Prognostic Significance of Combining Cytokeratin-19, E-Cadherin and Ki-67 Analysis in Triple-Negative Breast Cancer with Basal-Like and Non-Basal-Like Phenotype.

E-cadherin Ki-67 Triple negative breast cancer basal like cytokeratin prognosis

Journal

Cancer investigation
ISSN: 1532-4192
Titre abrégé: Cancer Invest
Pays: England
ID NLM: 8307154

Informations de publication

Date de publication:
22 Oct 2024
Historique:
medline: 22 10 2024
pubmed: 22 10 2024
entrez: 22 10 2024
Statut: aheadofprint

Résumé

Triple-negative breast cancer (TNBC) is known to have the worst outcome compared to the other forms of breast cancer. Moreover, molecular markers identified basal-like breast cancer (BLBC) phenotypes to be also related to a worse prognosis. In this study, we evaluated by immunohistochemistry (IHC) the prognostic significance of combining Cytokeratin-19 (CK19), E-cadherin, and Ki-67 tissue expression in triple-negative breast cancer (TNBC) cases presenting a basal-like (BLBC) or a non-basal-like (n-BLBC) phenotype to improve the selection and the monitoring of BC patients with a more aggressive outcome. Herein, when compared to n-BLBC, patients with BLBC showed a positive correlation with lymph node metastasis occurrence and lower survival rates. Immunohistochemistry analysis revealed significantly lower E-cadherin prevalence and higher prevalence of both CK19 and Ki-67 in BLBC when compared to n-BLBC. Spearman correlation showed that E-cadherin is negatively and significantly correlated to CK19 and Ki-67 expressions. Moreover, in BLBC, expressing both CK19 and Ki-67 combined with E-cadherin loss was associated with the worst relapse-free and overall survival. In conclusion, TNBC/BLBC phenotypes simultaneously losing E-cadherin and overexpressing CK19 and Ki-67 markers are the most aggressive forms. This combined analysis could be a predictive marker of poor prognosis.

Identifiants

pubmed: 39435793
doi: 10.1080/07357907.2024.2416166
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-13

Auteurs

Zahra Klayech (Z)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
Higher Institute of Biotechnology of Monastir, Monastir University, Monastir, Tunisia.

Adnene Moussa (A)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
Department of Anatomy and Pathologic Cytology, Fattouma Bourguiba University Hospital, Monastir University, Monastir, Tunisia.

Moufida Souid (M)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
Higher Institute of Biotechnology of Monastir, Monastir University, Monastir, Tunisia.

Rim Hadhri (R)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
Department of Anatomy and Pathologic Cytology, Fattouma Bourguiba University Hospital, Monastir University, Monastir, Tunisia.

Souad Miled (S)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
Department of Anatomy and Pathologic Cytology, Fattouma Bourguiba University Hospital, Monastir University, Monastir, Tunisia.

Sallouha Gabbouj (S)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.

Yassmine Remadi (Y)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.

Raja Faleh (R)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
Department of Gynecology and Obstetrics, Fattouma Bourguiba University Hospital, Monastir University, Monastir, Tunisia.

Noureddine Bouaouina (N)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
Ibn Khaldoun Medical Center of Cancerology, Sousse, Tunisia.

Abdelfattah Zakhama (A)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
Department of Anatomy and Pathologic Cytology, Fattouma Bourguiba University Hospital, Monastir University, Monastir, Tunisia.

Elham Hassen (E)

Molecular Immuno-Oncology Laboratory, Monastir University, Monastir, Tunisia.
Higher Institute of Biotechnology of Monastir, Monastir University, Monastir, Tunisia.

Classifications MeSH